Presentation is loading. Please wait.

Presentation is loading. Please wait.

Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory.

Similar presentations


Presentation on theme: "Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory."— Presentation transcript:

1 Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory disease? Novel doublets ± corticosteroids Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center

2 Disclosures Consulting: AMGEN, Genzyme, BMS, Otsuka, Celgene, Medtronic, Lilly, Millennium, Binding Site, Onyx, Bayer Speakers Bureaus: None Research: Cylene, Proteolix Patent for FISH based prognostication in MM - about $1500 per year Registered independent Believe in stem cell transplant Dislike wasting your time with this slide

3

4

5 POM-V-D 1-4 lines of Rx (median 2) Refractory to lenalidomide (67% progressed as last Rx) Not to bortezomib >= 2 cycles bortezomib 28 pts enrolled, 20 evaluable for response Bortezomib d 1, 4, 8, &11 1 & 8 after cycle 8

6 POM-V-D MTD pomalidomide 4 mg and bortezomib 1.3 mg/m2 ORR is 75% 30% VGPR or better One sCR TTR is 1 month Need larger randomized trials

7 A Phase I/II Trial of Pomalidomide, Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Joseph Mikhael MD1, Vivek Roy2, MD; Paul Richardson MD3; Andrzej Jakubowiak, MD4; Kristina Laumann5, Betsy LaPlant5; Angela Dispenzieri, MD5; S. Vincent Rajkumar, MD5; Rafael Fonseca, MD1; Nelson Leung, MD5; Francis K. Buadi, MD5, P. Leif Bergsagel; MD1, Robert A. Kyle, MD5; Thomas E. Witzig, MD5; Craig B. Reeder, MD; John A. Lust, MD, PhD5; Stephen J. Russell, MD, PhD5; Suzanne R. Hayman, MD5; Shaji Kumar, MD5; David Dingli, MD, PhD5; Stephen M. Ansell, MD, PhD5, Robert J. Dalton, MD5; Yi Lin, MD, PhD5, Taimur Sher, MD2, Prashant Kapoor, MD5, Arleigh McCurdy, MD5; Asher Chanan-Khan, MD2, A. Keith Stewart, MBCHB1; Morie A. Gertz, MD5, Martha Q. Lacy MD5

8 Results A total of 25 patients have been accrued to the trial: 9 in phase I (3 at dose level 1 and 6 at dose level 2) 16 additional at dose level 2 for 22 total in phase II.

9 Results Phase I For the 9 patients in Phase I: Response in Phase I:
Median age was 63 33% were mSMART intermediate or high risk Median number of prior regimens was 3 All patients had been treated with steroids and lenalidomide 89% had received and autologous stem cell transplant Response in Phase I: 8/9 pts responded (5CR, 2 VGPR and 1 PR)

10 Results – Phase II For the 16 patients at dose level 2:
median age was 66, 31% percent had mSMART defined high risk status Median prior lines of therapy was 3 (1-6), 100% treated with lenalidomide, 75% had stem cell transplant 50% had bortezomib 31% received thalidomide Response rate is 94%: 5 CR, 4 VGPR and 6 PR.

11 Car-Pom-d

12 Car-Pom-d

13 Car-Pom-d

14 Car-Pom-d

15 Car-Pom-d

16 Car-Pom-d

17 Summary Combinatorial strategies probably best Unprecedented ability to induce response Good DOR Much more progress is needed!


Download ppt "Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory."

Similar presentations


Ads by Google